查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600935

玻糖醛酸酶市场：按类型、给药途径、应用和最终用途分类 - 2025-2030 年全球预测

Hyaluronidase Market by Type (Animal-Derived Hyaluronidase, Synthetic Hyaluronidase), Route of Administration (Injection Route, Subcutaneous Route), Application, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年玻糖醛酸酶市值为10.1亿美元，预计2024年将达11.6亿美元，复合年增长率为14.43%，预计2030年将达26.2亿美元。

玻糖醛酸酶是指一组催化透明质酸降解的酶，主要用于增加组织渗透性，促进其他注射药物的分散，并增强局部麻醉剂的效果。玻糖醛酸酶在眼科手术、真皮填充剂製备和肿瘤治疗等医疗和美容手术中的重要作用强调了对透明质酸酶的需求。其应用涵盖多个行业，包括製药、化妆品和诊断等主要最终用途领域。市场洞察表明，对微创和非手术美容手术的需求不断增长是玻糖醛酸酶市场的关键驱动因素。此外，癌症盛行率的增加和肿瘤学的进步正在推动市场扩张，因为玻糖醛酸酶显着增强了化疗药物的疗效。最新的商机在于个人化医疗的成长趋势以及利用玻糖醛酸酶促进药物分散的新型递送系统的开发。然而，市场成长受到高製造成本、潜在副作用和严格法律规范等挑战的阻碍。此外，某些地区的意识低和缺乏训练有素的专业人员也可能阻碍市场渗透。为了实现业务成长，有些领域需要技术创新和研究，例如开发重组玻糖醛酸酶产品、提高酵素稳定性以及在正在开发医疗基础设施的开发中国家扩大应用。此外，探索玻糖醛酸酶与新配方和药物传输技术的融合可能会提供竞争优势。市场竞争非常激烈，许多参与者都致力于创新，这凸显出需要进行严格的市场研究和策略伙伴关係，以利用新兴趋势并克服现有挑战。

主要市场统计
基准年[2023] 10.1亿美元
预测年份 [2024] 11.6亿美元
预测年份 [2030] 26.2亿美元
复合年增长率（%） 14.43%

市场动态：揭示快速发展的玻糖醛酸酶市场的关键市场洞察

供需的动态交互作用正在改变玻糖醛酸酶市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 消费者对化妆品和美容护理的偏好不断增加
    • 扩大药品生产和利用玻糖醛酸酶促进药物吸收
    • 玻糖醛酸酶产品获得监管部门的有利核准
  • 市场限制因素
    • 製造和配製玻糖醛酸酶解决方案的问题
  • 市场机会
    • 持续创新和临床试验以提高玻糖醛酸酶的功能和效率
    • 在眼科手术中使用玻糖醛酸酶的可能性以及提高玻糖醛酸酶认识的努力
  • 市场挑战
    • 玻糖醛酸酶可能出现过敏反应和性能问题

波特五力：驾驭玻糖醛酸酶市场的策略工具

波特的五力框架是了解玻糖醛酸酶市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解玻糖醛酸酶市场的外部影响

外部宏观环境因素在塑造玻糖醛酸酶市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解玻糖醛酸酶市场的竞争状况

对玻糖醛酸酶市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵玻糖醛酸酶市场供应商绩效评估

FPNV定位矩阵是评估玻糖醛酸酶市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了玻糖醛酸酶市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，玻糖醛酸酶市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 消费者对整容手术的兴趣日益浓厚
      • 利用玻糖醛酸酶扩大药物生产并促进药物吸收
      • 玻糖醛酸酶产品的监管核准
    • 抑制因素
      • 与创建和配製玻糖醛酸酶解决方案相关的问题
    • 机会
      • 持续创新和临床试验以提高玻糖醛酸酶的功能和效率
      • 玻糖醛酸酶在眼科手术中的潜在用途以及提高玻糖醛酸酶认识的努力
    • 任务
      • 可能的玻糖醛酸酶酶过敏反应和性能问题
  • 市场区隔分析
    • 类型：生物技术和伦理考虑的不断进步导致更多地采用合成玻糖醛酸酶
    • 给药途径：临床实务中优选注射途径，因为全身性作用发生得更快。
    • 应用：玻糖醛酸酶在美容手术和皮肤病治疗的新多功能应用
    • 最终用途：扩大世界各地医院和诊所提供的服务和医疗程序
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章玻糖醛酸酶市场：依类型

  • 动物源性玻糖醛酸酶
  • 合成玻糖醛酸酶酶

第七章玻糖醛酸酶市场：依给药途径

  • 注射途径
  • 皮下给药

第八章玻糖醛酸酶市场：依应用分类

  • 化疗
  • 皮肤科
  • 眼科
  • 整形外科

第九章玻糖醛酸酶市场：依最终用途

  • 门诊手术中心
  • 医院/诊所

第10章美洲玻糖醛酸酶市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区玻糖醛酸酶市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲玻糖醛酸酶市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Creative Enzymes 介绍重组人类玻糖醛酸酶PH20
    • 强生公司针对 Darzalex Faspro 的 sBLA 申请
    • 癌症治疗的突破：3 期研究证明皮下注射 Nivolumab 在肾细胞癌的非劣效性
    • 日本厚生劳动省核准VYVDURA 扩大了 gMG 患者的治疗选择
    • 核准将 HYQVIA 的用途扩大到 CIDP 维持治疗
    • 中外製药的Phesgo在日本上市，为 HER2 阳性癌症的治疗带来革命性进展
    • Acumen Pharmaceuticals 与 Halozyme 合作增强阿兹海默症的治疗效果
    • Arteogen 的 Telgase 在 ADA 发生率为零的临床试验中显示出可喜的结果
    • Arteogen 和 Sandoz 结成策略联盟，共同开发皮下生物相似药
  • 战略分析和建议
    • 默克
    • 恩法斯特製药有限公司
    • 库柏外科有限公司
    • Halozyme 治疗公司
    • 博士健康公司有限公司

公司名单

  • Alteogen Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Argenx SE
  • Bausch Health Companies Inc.
  • BBI Solutions by Novo Holdings A/S
  • Bioindustria LIM spa
  • Cell Signaling Technology, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • CooperSurgical, Inc.
  • Creative Enzymes
  • Ferro Pharma GmbH
  • FUJIFILM Holdings Corporation
  • Glentham Life Sciences Limited
  • GYNEMED GmbH & Co. KG by Hamilton Thorne Ltd.
  • Halozyme Therapeutics, Inc.
  • Innovative Research
  • Johnson & Johnson Services, Inc.
  • Kitazato Corporation
  • Kraeber & Co GmbH
  • Laboratorio Innoaesthetics, SLU
  • Merck KGaA
  • Sanofi
  • Shreya Life Sciences Pvt. Ltd
  • STEMCELL Technologies Canada Inc.
  • Sun Pharmaceutical Industries Limited
  • Sunways（India）Private Limited
  • Taj Pharmaceuticals Ltd.
  • Takeda Pharmaceutical Company Limited
  • Wockhardt Limited
  • Worthington Biochemical Corporation
Product Code: MRR-22146147668D

The Hyaluronidase Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.16 billion in 2024, and is projected to grow at a CAGR of 14.43%, to USD 2.62 billion by 2030.

Hyaluronidase refers to a group of enzymes that catalyze the degradation of hyaluronic acid, predominantly used to increase tissue permeability, promote the dispersion of other injected drugs, and enhance the efficacy of local anesthetics. The necessity of hyaluronidase is underscored by its critical role in medical and aesthetic procedures, including ophthalmic surgeries, dermal filler adjustments, and oncology treatments. Its application spans across various industries, with key end-use sectors including pharmaceuticals, cosmetics, and diagnostics. The market insights reveal that the growing demand for minimally invasive and non-surgical aesthetic procedures is a significant driver for the Hyaluronidase market. Furthermore, the increasing prevalence of cancer and advancements in oncology are fostering the market expansion, as hyaluronidase significantly enhances the efficacy of chemotherapeutic agents. The latest opportunities lie in the rising trend of personalized medicine and the development of novel delivery systems that leverage hyaluronidase's ability to promote drug dispersion. However, market growth is challenged by factors such as high production costs, potential adverse reactions, and stringent regulatory frameworks. Limitations also include the lack of awareness and trained professionals in some regions, which may hinder market penetration. For business growth, areas ripe for innovation and research include the development of recombinant hyaluronidase products, improving enzyme stability, and expanding applications in developing countries where healthcare infrastructure is improving. Additionally, exploring the integration of hyaluronidase with new drug formulations and delivery technologies can present competitive advantages. The market is highly competitive with numerous players striving for innovation, thus emphasizing the necessity for rigorous market research and strategic partnerships to capitalize on emerging trends and overcome existing challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.16 billion
Forecast Year [2030] USD 2.62 billion
CAGR (%) 14.43%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hyaluronidase Market

The Hyaluronidase Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing consumer inclination toward cosmetic and aesthetic procedures
    • Expanding production of drugs and utilization of hyaluronidase to promote drug absorption
    • Favorable regulatory approvals for hyaluronidase products
  • Market Restraints
    • Issues associated with the production and formulation of hyaluronidase solutions
  • Market Opportunities
    • Ongoing innovations and clinical trials to improve the functionality and efficiency of hyaluronidase
    • Potential for utilization of hyaluronidase in ophthalmic surgeries and efforts to raise awareness for hyaluronidase
  • Market Challenges
    • Possibility of allergic reactions and performance issues of hyaluronidase

Porter's Five Forces: A Strategic Tool for Navigating the Hyaluronidase Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hyaluronidase Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hyaluronidase Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hyaluronidase Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hyaluronidase Market

A detailed market share analysis in the Hyaluronidase Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hyaluronidase Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hyaluronidase Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hyaluronidase Market

A strategic analysis of the Hyaluronidase Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hyaluronidase Market, highlighting leading vendors and their innovative profiles. These include Alteogen Inc., Amphastar Pharmaceuticals, Inc., Argenx SE, Bausch Health Companies Inc., BBI Solutions by Novo Holdings A/S, Bioindustria L.I.M. spa, Cell Signaling Technology, Inc., Chugai Pharmaceutical Co., Ltd., CooperSurgical, Inc., Creative Enzymes, Ferro Pharma GmbH, FUJIFILM Holdings Corporation, Glentham Life Sciences Limited, GYNEMED GmbH & Co. KG by Hamilton Thorne Ltd., Halozyme Therapeutics, Inc., Innovative Research, Johnson & Johnson Services, Inc., Kitazato Corporation, Kraeber & Co GmbH, Laboratorio Innoaesthetics, S.L.U., Merck KGaA, Sanofi, Shreya Life Sciences Pvt. Ltd, STEMCELL Technologies Canada Inc., Sun Pharmaceutical Industries Limited, Sunways (India) Private Limited, Taj Pharmaceuticals Ltd., Takeda Pharmaceutical Company Limited, Wockhardt Limited, and Worthington Biochemical Corporation.

Market Segmentation & Coverage

This research report categorizes the Hyaluronidase Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Animal-Derived Hyaluronidase and Synthetic Hyaluronidase.
  • Based on Route of Administration, market is studied across Injection Route and Subcutaneous Route.
  • Based on Application, market is studied across Chemotherapy, Dermatology, Ophthalmology, and Plastic Surgery.
  • Based on End-Use, market is studied across Ambulatory Surgical Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing consumer inclination toward cosmetic and aesthetic procedures
      • 5.1.1.2. Expanding production of drugs and utilization of hyaluronidase to promote drug absorption
      • 5.1.1.3. Favorable regulatory approvals for hyaluronidase products
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with the production and formulation of hyaluronidase solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing innovations and clinical trials to improve the functionality and efficiency of hyaluronidase
      • 5.1.3.2. Potential for utilization of hyaluronidase in ophthalmic surgeries and efforts to raise awareness for hyaluronidase
    • 5.1.4. Challenges
      • 5.1.4.1. Possibility of allergic reactions and performance issues of hyaluronidase
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Expanding adoption of synthetic hyaluronidase owing to ongoing advancements in biotechnology and ethical considerations
    • 5.2.2. Route of Administration: Preference for injection route in clinical settings owing to its quicker systemic effects
    • 5.2.3. Application: Emerging versatile applications of hyaluronidase in dermatology for cosmetic procedures and treatment of skin conditions
    • 5.2.4. End-Use: Expansion of services and medical treatments offered by hospitals and clinics worldwide
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hyaluronidase Market, by Type

  • 6.1. Introduction
  • 6.2. Animal-Derived Hyaluronidase
  • 6.3. Synthetic Hyaluronidase

7. Hyaluronidase Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injection Route
  • 7.3. Subcutaneous Route

8. Hyaluronidase Market, by Application

  • 8.1. Introduction
  • 8.2. Chemotherapy
  • 8.3. Dermatology
  • 8.4. Ophthalmology
  • 8.5. Plastic Surgery

9. Hyaluronidase Market, by End-Use

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals & Clinics

10. Americas Hyaluronidase Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hyaluronidase Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hyaluronidase Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Introduction of Recombinant Human Hyaluronidase PH20 by Creative Enzymes
    • 13.3.2. Johnson & Johnson's sBLA Submission for Darzalex Faspro
    • 13.3.3. Breakthrough in Cancer Treatment with Phase 3 Trial Demonstrates Noninferiority of Subcutaneous Nivolumab in Renal Cell Carcinoma
    • 13.3.4. Approval of VYVDURA by Japan's MHLW Expands Treatment Options for gMG Patients
    • 13.3.5. Approval Expands HYQVIA Use to Maintenance Therapy for CIDP
    • 13.3.6. Revolutionary Advancement in HER2-Positive Cancer Treatment by Chugai's Launch of Phesgo in Japan
    • 13.3.7. Acumen Pharmaceuticals Partners with Halozyme to Enhance Alzheimer's Treatment Delivery
    • 13.3.8. Alteogen Inc.'s Tergase Shows Promising Results in Clinical Trials with Zero ADA Incidence
    • 13.3.9. Strategic Collaboration Between Alteogen Inc. and Sandoz AG for Licensing and Development of Subcutaneous Biosimilars
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Merck KGaA
    • 13.4.2. Amphastar Pharmaceuticals, Inc.
    • 13.4.3. CooperSurgical, Inc.
    • 13.4.4. Halozyme Therapeutics, Inc.
    • 13.4.5. Bausch Health Companies Inc.

Companies Mentioned

  • 1. Alteogen Inc.
  • 2. Amphastar Pharmaceuticals, Inc.
  • 3. Argenx SE
  • 4. Bausch Health Companies Inc.
  • 5. BBI Solutions by Novo Holdings A/S
  • 6. Bioindustria L.I.M. spa
  • 7. Cell Signaling Technology, Inc.
  • 8. Chugai Pharmaceutical Co., Ltd.
  • 9. CooperSurgical, Inc.
  • 10. Creative Enzymes
  • 11. Ferro Pharma GmbH
  • 12. FUJIFILM Holdings Corporation
  • 13. Glentham Life Sciences Limited
  • 14. GYNEMED GmbH & Co. KG by Hamilton Thorne Ltd.
  • 15. Halozyme Therapeutics, Inc.
  • 16. Innovative Research
  • 17. Johnson & Johnson Services, Inc.
  • 18. Kitazato Corporation
  • 19. Kraeber & Co GmbH
  • 20. Laboratorio Innoaesthetics, S.L.U.
  • 21. Merck KGaA
  • 22. Sanofi
  • 23. Shreya Life Sciences Pvt. Ltd
  • 24. STEMCELL Technologies Canada Inc.
  • 25. Sun Pharmaceutical Industries Limited
  • 26. Sunways (India) Private Limited
  • 27. Taj Pharmaceuticals Ltd.
  • 28. Takeda Pharmaceutical Company Limited
  • 29. Wockhardt Limited
  • 30. Worthington Biochemical Corporation

LIST OF FIGURES

  • FIGURE 1. HYALURONIDASE MARKET RESEARCH PROCESS
  • FIGURE 2. HYALURONIDASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HYALURONIDASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HYALURONIDASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HYALURONIDASE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HYALURONIDASE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HYALURONIDASE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HYALURONIDASE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HYALURONIDASE MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HYALURONIDASE MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HYALURONIDASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HYALURONIDASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HYALURONIDASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HYALURONIDASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HYALURONIDASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HYALURONIDASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HYALURONIDASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HYALURONIDASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HYALURONIDASE MARKET DYNAMICS
  • TABLE 7. GLOBAL HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HYALURONIDASE MARKET SIZE, BY ANIMAL-DERIVED HYALURONIDASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HYALURONIDASE MARKET SIZE, BY SYNTHETIC HYALURONIDASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HYALURONIDASE MARKET SIZE, BY INJECTION ROUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HYALURONIDASE MARKET SIZE, BY SUBCUTANEOUS ROUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HYALURONIDASE MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HYALURONIDASE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HYALURONIDASE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HYALURONIDASE MARKET SIZE, BY PLASTIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HYALURONIDASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HYALURONIDASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HYALURONIDASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HYALURONIDASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 189. HYALURONIDASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. HYALURONIDASE MARKET, FPNV POSITIONING MATRIX, 2023